These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12953130)

  • 1. FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia.
    Tanner ML; Hoh CK; Bashey A; Holman P; Sun C; Broome HE; Lane T; Ball ED; Carrier E
    Bone Marrow Transplant; 2003 Sep; 32(6):581-5. PubMed ID: 12953130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.
    Hessling J; Kröger N; Werner M; Zabelina T; Hansen A; Kordes U; Ayuk FA; Renges H; Panse J; Erttmann R; Zander AR
    Br J Haematol; 2002 Dec; 119(3):769-72. PubMed ID: 12437657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
    Anderlini P; Giralt S; Andersson B; Ueno NT; Khouri I; Acholonu S; Cohen A; Körbling MJ; Manning J; Romaguera J; Sarris A; Rodriguez ; Hagemeister F; Mclaughlin P; Cabanillas F; Champlin RE
    Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment with nonmyeloablative allogeneic hematopoietic stem cell transplantation in a patient with acute myeloid leukemia complicated with pulmonary infection.
    Choi I; Abe Y; Ohtsuka R; Matsushima T; Tachikawa Y; Nagasawa E; Nishimura J; Inaba S; Nawata H; Muta K
    Int J Hematol; 2004 Jan; 79(1):92-4. PubMed ID: 14979485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
    Kröger N; Thiele J; Zander A; Schwerdtfeger R; Kobbe G; Bornhäuser M; Bethge W; Schubert J; de Witte T; Kvasnicka HM;
    Exp Hematol; 2007 Nov; 35(11):1719-22. PubMed ID: 17976523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.
    Nagi W; Lim ZY; Krishnamurthy P; Potter V; Tindell V; Reiff-Zall L; Abdullah A; Lea N; Kenyon M; Marsh J; Ho AY; Mufti GJ; Pagliuca A
    Leuk Res; 2011 Aug; 35(8):998-1000. PubMed ID: 21704371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.
    Devine SM; Hoffman R; Verma A; Shah R; Bradlow BA; Stock W; Maynard V; Jessop E; Peace D; Huml M; Thomason D; Chen YH; van Besien K
    Blood; 2002 Mar; 99(6):2255-8. PubMed ID: 11877308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
    Kato K; Yoshida N; Matsumoto K; Matsuyama T
    Pediatr Blood Cancer; 2014 Apr; 61(4):712-6. PubMed ID: 24376191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of marrow fibrosis in agnogenic myeloid metaplasia by allogeneic peripheral blood stem cell transplantation.
    Udomsakdi-Auewarakul C; Visuthisakchai S; Sangruchi T; Issaragrisil S
    Asian Pac J Allergy Immunol; 2003 Jun; 21(2):121-6. PubMed ID: 14629130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Barosi G; Bacigalupo A
    Curr Opin Hematol; 2006 Mar; 13(2):74-8. PubMed ID: 16456372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.
    Ruiz-Argüelles GJ; Gómez-Almaguer D; Ruiz-Argüelles A; González-Llano O; Cantú OG; Jaime-Pérez JC
    Am J Hematol; 2001 Apr; 66(4):241-4. PubMed ID: 11279633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
    Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
    Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
    Hambach L; Eder M; Dammann E; Battmer K; Stucki A; Heil G; Ganser A; Hertenstein B
    Bone Marrow Transplant; 2001 Oct; 28(7):705-7. PubMed ID: 11704795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-TBI stem cell transplantation protocol for Fanconi anaemia using HLA-compatible sibling and unrelated donors.
    de la Fuente J; Reiss S; McCloy M; Vulliamy T; Roberts IA; Rahemtulla A; Dokal I
    Bone Marrow Transplant; 2003 Oct; 32(7):653-6. PubMed ID: 13130311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful immunotherapy in early relapse of acute myeloid leukemia after nonmyeloablative allogeneic stem cell transplantation.
    Prinz E; Keil F; Kalhs P; Mitterbauer M; Rabitsch W; Rosenmayr A; Moser K; Schulenburg A; Lechner K; Greinix HT
    Ann Hematol; 2003 May; 82(5):295-8. PubMed ID: 12679886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
    Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
    Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.